← All trials
NCT05892913
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 19, 2023
- Primary completion
- Oct 10, 2023
- Completion date
- Oct 10, 2023
- First posted
- Jun 7, 2023
- Last posted
- Oct 11, 2023
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Abant Izzet Baysal UniversityLead sponsor
- Abant Izzet Baysal UniversityReponsible party - principal investigator
- Abant Izzet Baysal UniversitySponsor investigator
- Abant Izzet Baysal UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.